$RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.

2024 Q3 Form 10-Q Financial Statement

#000143774924026571 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.604M $2.545M
YoY Change -19.46% -17.34%
% of Gross Profit
Research & Development $6.858M $5.584M
YoY Change -21.33% -37.89%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $8.463M $8.130M
YoY Change -20.98% -32.65%
Operating Profit -$8.463M -$8.130M
YoY Change -20.98% -32.65%
Interest Expense $48.10K $82.46K
YoY Change 715.12% 546.29%
% of Operating Profit
Other Income/Expense, Net $96.74K $277.1K
YoY Change -57.97% -175.74%
Pretax Income -$8.366M -$7.853M
YoY Change -20.17% -36.86%
Income Tax $0.00 $7.385K
% Of Pretax Income
Net Earnings -$8.366M -$7.860M
YoY Change -20.33% -36.61%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25 -$0.26
Diluted Earnings Per Share -$0.25 -$0.26
COMMON SHARES
Basic Shares Outstanding 29.82M 27.92M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.559M $6.178M
YoY Change 11.8% -44.6%
Cash & Equivalents $5.559M $6.178M
Short-Term Investments
Other Short-Term Assets $1.251M $1.055M
YoY Change 201.71% 52.77%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.810M $7.233M
YoY Change 26.42% -38.92%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $819.7K $819.7K
YoY Change
Total Long-Term Assets $819.7K $819.7K
YoY Change 81972000.0% 40985950.0%
TOTAL ASSETS
Total Short-Term Assets $6.810M $7.233M
Total Long-Term Assets $819.7K $819.7K
Total Assets $7.630M $8.053M
YoY Change 41.63% -32.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.778M $4.693M
YoY Change 66.29% 77.22%
Accrued Expenses $8.673M $9.043M
YoY Change 15.15% 42.69%
Deferred Revenue
YoY Change
Short-Term Debt $83.00K $207.5K
YoY Change -62.7% -6.74%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.53M $13.94M
YoY Change 34.53% 51.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $77.88K $150.2K
YoY Change -91.08% -85.16%
Total Long-Term Liabilities $77.88K $150.2K
YoY Change -91.08% -85.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.53M $13.94M
Total Long-Term Liabilities $77.88K $150.2K
Total Liabilities $17.61M $14.09M
YoY Change 26.64% 37.9%
SHAREHOLDERS EQUITY
Retained Earnings -$158.0M -$149.6M
YoY Change 30.9% 35.75%
Common Stock $3.344K $2.982K
YoY Change 47.64% 31.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.982M -$6.042M
YoY Change
Total Liabilities & Shareholders Equity $7.630M $8.053M
YoY Change 41.63% -32.0%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$8.366M -$7.860M
YoY Change -20.33% -36.61%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.241M -$8.476M
YoY Change -31.35% 59.41%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.622M 2.681M
YoY Change 1034774.29% -48.58%
NET CHANGE
Cash From Operating Activities -4.241M -8.476M
Cash From Investing Activities
Cash From Financing Activities 3.622M 2.681M
Net Change In Cash -619.4K -5.795M
YoY Change -89.97% 5474.71%
FREE CASH FLOW
Cash From Operating Activities -$4.241M -$8.476M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5584347 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8256336 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001742927
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
819721 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
0 usd
CY2024Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
207500 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1295978 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13943991 usd
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
150205 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2792 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2545296 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3079301 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
8129643 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11335637 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8129643 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11335637 usd
CY2024Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
200273 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
5153 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
12759 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
87610 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
103080 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5621 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-365875 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7852534 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11701512 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7385 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6436 usd
CY2024Q2 us-gaap Liabilities
Liabilities
14094196 usd
CY2023Q4 us-gaap Liabilities
Liabilities
17981672 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27918560
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2982 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11368212 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13740481 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2545296 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3079301 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4683537 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4579855 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
8129643 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11335637 usd
us-gaap Operating Expenses
OperatingExpenses
16051749 usd
us-gaap Operating Expenses
OperatingExpenses
18320336 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8129643 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11335637 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16051749 usd
CY2024Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
200273 usd
CY2023Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-456177 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
5153 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
12759 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
8640 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
20414 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
87610 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
103080 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
260708 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
250091 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5621 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-135515 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14513 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
277109 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-365875 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
773003 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-229887 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7852534 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11701512 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15278746 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18550223 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7385 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7859919 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11707948 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14781 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7859919 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11707948 usd
us-gaap Net Income Loss
NetIncomeLoss
-15293527 usd
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30555012
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1345817 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1494482 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1081689 usd
CY2024Q2 rvph Adjustments To Additional Paid In Capital Modification Of Existing Warrants
AdjustmentsToAdditionalPaidInCapitalModificationOfExistingWarrants
229050 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
358993 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7859919 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5718716 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1494482 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1081689 usd
rvph Adjustments To Additional Paid In Capital Modification Of Existing Warrants
AdjustmentsToAdditionalPaidInCapitalModificationOfExistingWarrants
229050 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
728068 usd
us-gaap Net Income Loss
NetIncomeLoss
-15293527 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6041522 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1613677 usd
CY2023Q2 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5658257 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2620819 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11707948 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1815195 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8394246 usd
rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5677850 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2672346 usd
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1815195 usd
us-gaap Net Income Loss
NetIncomeLoss
-15293527 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-656450 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
445051 usd
us-gaap Share Based Compensation
ShareBasedCompensation
728068 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2672346 usd
rvph Increase Decrease In Prepaid Clinical Study Costs
IncreaseDecreaseInPrepaidClinicalStudyCosts
1270373 usd
rvph Increase Decrease In Prepaid Clinical Study Costs
IncreaseDecreaseInPrepaidClinicalStudyCosts
-0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
271189 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30555012
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22434781
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30221168
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22135850
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1345817 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1494482 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1081689 usd
CY2024Q2 rvph Adjustments To Additional Paid In Capital Modification Of Existing Warrants
AdjustmentsToAdditionalPaidInCapitalModificationOfExistingWarrants
229050 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
358993 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7859919 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6041522 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5718716 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1494482 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1081689 usd
rvph Adjustments To Additional Paid In Capital Modification Of Existing Warrants
AdjustmentsToAdditionalPaidInCapitalModificationOfExistingWarrants
229050 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
728068 usd
us-gaap Net Income Loss
NetIncomeLoss
-15293527 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6041522 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1613677 usd
CY2023Q2 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5658257 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2620819 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11707948 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1815195 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8394246 usd
rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5677850 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2672346 usd
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1815195 usd
us-gaap Net Income Loss
NetIncomeLoss
-15293527 usd
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-656450 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
445051 usd
us-gaap Share Based Compensation
ShareBasedCompensation
728068 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2672346 usd
rvph Increase Decrease In Prepaid Clinical Study Costs
IncreaseDecreaseInPrepaidClinicalStudyCosts
1270373 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
271189 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
286621 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
844252 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-871984 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3332221 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20201997 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13268624 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
415000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
667500 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
207500 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
445000 usd
rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
2805221 usd
rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5677850 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3012721 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5900350 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-17189276 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
286621 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
844252 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-871984 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-4282778 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3332221 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20201997 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13268624 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
415000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
667500 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
207500 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
445000 usd
rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
2805221 usd
rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5677850 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3012721 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5900350 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-17189276 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7368274 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23367456 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6178180 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11151582 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3417 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3941 usd
us-gaap Interest Paid Net
InterestPaidNet
8640 usd
us-gaap Interest Paid Net
InterestPaidNet
20414 usd
rvph Warrant Modification
WarrantModification
229050 usd
rvph Warrant Modification
WarrantModification
0 usd
rvph Warrants Issued
WarrantsIssued
1081689 usd
rvph Warrants Issued
WarrantsIssued
0 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Reclassifications</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain amounts in the prior year’s consolidated financial statements, as of December 31, 2023 have been reclassified to conform to the current period's presentation. This involved disclosing separately, prepaid clinical trial costs from the prepaid expenses and other current assets balance, which were previously disclosed in the aggregate. This reclassification had no effect on the Company’s loss from operations, net loss, or net loss per share.</p>
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7368274 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23367456 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18519856 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6178180 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11151582 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3417 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3941 usd
us-gaap Interest Paid Net
InterestPaidNet
8640 usd
rvph Warrant Modification
WarrantModification
229050 usd
rvph Warrant Modification
WarrantModification
0 usd
rvph Warrants Issued
WarrantsIssued
1081689 usd
rvph Warrants Issued
WarrantsIssued
0 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Reclassifications</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain amounts in the prior year’s consolidated financial statements, as of December 31, 2023 have been reclassified to conform to the current period's presentation. This involved disclosing separately, prepaid clinical trial costs from the prepaid expenses and other current assets balance, which were previously disclosed in the aggregate. This reclassification had no effect on the Company’s loss from operations, net loss, or net loss per share.</p>
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8256336 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11335637 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11335637 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11707948 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13740481 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8256336 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11335637 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11335637 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11707948 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13740481 usd
us-gaap Operating Expenses
OperatingExpenses
18320336 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18320336 usd
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3332221 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13268624 usd
CY2024Q2 rvph Working Capital
WorkingCapital
6700000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149600000 usd
CY2024Q2 us-gaap Cash
Cash
6200000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7900000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11700000 usd
us-gaap Net Income Loss
NetIncomeLoss
-18600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, accounting for clinical trial costs, assumptions used to calculate the fair value of stock-based compensation, assumptions used to calculate the fair value of warrants, deferred taxes, and related valuation allowances. Actual results could differ materially from such estimates under different assumptions or circumstances.</p>
us-gaap Operating Expenses
OperatingExpenses
18320336 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18320336 usd
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3332221 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13268624 usd
CY2024Q2 rvph Working Capital
WorkingCapital
6700000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149600000 usd
CY2024Q2 us-gaap Cash
Cash
6200000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7900000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11700000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-18600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, accounting for clinical trial costs, assumptions used to calculate the fair value of stock-based compensation, assumptions used to calculate the fair value of warrants, deferred taxes, and related valuation allowances. Actual results could differ materially from such estimates under different assumptions or circumstances.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially, all the Company’s cash and cash equivalents are held in demand deposit and money market funds at three financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. Amounts held in demand deposit in excess of federally insured limits, totaled $915,028 and $786,971 as of June 30, 2024 and December 31, 2023, respectively. The Company has not experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors.</p>
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
915028 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
786971 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially, all the Company’s cash and cash equivalents are held in demand deposit and money market funds at three financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. Amounts held in demand deposit in excess of federally insured limits, totaled $915,028 and $786,971 as of June 30, 2024 and December 31, 2023, respectively. The Company has not experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors.</p>
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
915028 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
786971 usd
CY2024Q2 us-gaap Cash And Due From Banks
CashAndDueFromBanks
1251654 usd
CY2023Q4 us-gaap Cash And Due From Banks
CashAndDueFromBanks
1155636 usd
CY2024Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4926526 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
22211820 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6178180 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23367456 usd
CY2024Q2 us-gaap Cash And Due From Banks
CashAndDueFromBanks
1251654 usd
CY2023Q4 us-gaap Cash And Due From Banks
CashAndDueFromBanks
1155636 usd
CY2024Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4926526 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
22211820 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6178180 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23367456 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7859919 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11707948 usd
us-gaap Net Income Loss
NetIncomeLoss
-15293527 usd
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30555012
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7859919 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11707948 usd
us-gaap Net Income Loss
NetIncomeLoss
-15293527 usd
us-gaap Net Income Loss
NetIncomeLoss
-18559637 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30555012
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22434781
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30221168
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22135850
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24288175
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17577983
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24288175
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17577983
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25067643
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.03
CY2023Q4 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
29686123 usd
CY2023 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y1M6D
rvph Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
1898734
rvph Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
1.46
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.52
CY2024Q2 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
2519822 usd
rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y9M18D
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22434781
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30221168
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22135850
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24288175
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24288175
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17577983
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25067643
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.03
CY2023Q4 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
29686123 usd
CY2023 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y1M6D
rvph Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
1898734
rvph Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
1.46
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
26966377
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.52
CY2024Q2 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
2519822 usd
rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y9M18D
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29817294
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
24751368
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1505572
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
30128061
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2600000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2700000 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2400000 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29817294
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
24751368
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1505572
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
30128061
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2600000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2700000 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2400000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
358993 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2620819 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
728068 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2672346 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
13100 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
5200 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
24300 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
10200 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
358993 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2620819 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
728068 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2672346 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
13100 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
24300 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
10200 usd

Files In Submission

Name View Source Status
0001437749-24-026571-index-headers.html Edgar Link pending
0001437749-24-026571-index.html Edgar Link pending
0001437749-24-026571.txt Edgar Link pending
0001437749-24-026571-xbrl.zip Edgar Link pending
ex_708377.htm Edgar Link pending
ex_708378.htm Edgar Link pending
ex_708379.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvph-20240630.xsd Edgar Link pending
rvph20240630_10q.htm Edgar Link pending
Show.js Edgar Link pending
rvph-20240630_cal.xml Edgar Link unprocessable
rvph-20240630_def.xml Edgar Link unprocessable
rvph-20240630_lab.xml Edgar Link unprocessable
rvph-20240630_pre.xml Edgar Link unprocessable
rvph20240630_10q_htm.xml Edgar Link completed